Crescent Capital BDC

CCAP · NASDAQ

$8.62−$0.08 (−0.92%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $8.70

CCAP analyst rating

HoldConsensus of 6 analysts over the last 12 months. 17% rate it a buy.

Strong buy0
Buy1
Hold5
Underperform0
Sell0

12-month price target · 10 analysts

Average $12.91 (+49.8% upside)

Low: $10.35
Now: $8.62
High: $16.27

Upgrades and downgrades

The latest rating actions, newest first

CCAP analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
B of A Securities	Sep 10, 2026	Downgrade	Buy → Neutral	$13.00 → $10.25	34%
Keefe, Bruyette & Woods	Aug 17, 2026	Downgrade	Outperform → Market Perform	$13.00 → $12.00	36%
Ladenburg Thalmann	Aug 12, 2026	Maintains	Buy	$15.00 → $14.00	29%
B. Riley Securities	Aug 12, 2026	Maintains	Neutral	$13.50 → $12.50	0%
Wells Fargo	Aug 12, 2026	Maintains	Equal-Weight	$12.00 → $11.00	50%
Keefe, Bruyette & Woods	Jun 16, 2026	Maintains	Outperform	$15.00 → $13.00	36%
Ladenburg Thalmann	May 15, 2026	Maintains	Buy	$16.00 → $15.00	29%
Oppenheimer	May 15, 2026	Downgrade	Outperform → Perform	$19.00 → $16.00	34%
Wells Fargo	May 15, 2026	Maintains	Equal-Weight	$13.00 → $12.00	50%
Keefe, Bruyette & Woods	Apr 16, 2026	Maintains	Outperform	$15.50 → $15.00	36%

The case for and against

Updated Oct 31, 2025

Bull case

Crescent Capital BDC reported a significant net growth of $27 million, surpassing expectations of $10 million, indicating a robust performance relative to forecasts. Additionally, the decline in KBW watchlist investments to 1.2% from 3.1% of cost suggests an improvement in the overall credit quality of the portfolio. Although there was an increase in non-accruals and investments rated below expectations, the positive net growth and improved metrics related to watchlist investments contribute to an optimistic outlook for the company.

Bear case

Crescent Capital BDC's net asset value (NAV) experienced a decline of $0.36, or 1.8%, falling to $19.62, primarily due to net portfolio losses and operating earnings that were insufficient to cover dividends paid. The company faces significant risk factors, particularly related to credit issues that could exceed expectations, further threatening its earnings, book value, and stock price. Although total non-accruals are currently at a manageable level of 3.3% at cost value, the rapid deterioration of several recent non-accruals raises concerns about the overall stability of the company's investment portfolio.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.